Recent non-core, business-related newsflow has proved highly beneficial to Medigene. The full and final transference of EndoTAG-1 rights to SynCore and the sale of its Catherex subsidiary to Amgen for $10.5m (40% to Medigene) tidies up its legacy pipeline and IP assets, while providing a decent revenue stream. Medigene’s core focus remains on its immuneoncology franchise, and we look forward to significant progress in 2016. Our rNPV-based valuation increases to €216m or €10.98
08 Feb 2016
Recent deals enable greater focus on the core
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Recent deals enable greater focus on the core
Recent non-core, business-related newsflow has proved highly beneficial to Medigene. The full and final transference of EndoTAG-1 rights to SynCore and the sale of its Catherex subsidiary to Amgen for $10.5m (40% to Medigene) tidies up its legacy pipeline and IP assets, while providing a decent revenue stream. Medigene’s core focus remains on its immuneoncology franchise, and we look forward to significant progress in 2016. Our rNPV-based valuation increases to €216m or €10.98